US 12,282,015 B2
Systems and methods for testing and screening using compound bound substrates
Anne North, Pleasant Hill, CA (US); and Naheed Mufti, Concord, CA (US)
Assigned to Cerus Corporation, Concord, CA (US)
Filed by Cerus Corporation, Concord, CA (US)
Filed on Sep. 6, 2023, as Appl. No. 18/243,045.
Application 18/243,045 is a division of application No. 16/472,813, abandoned, previously published as PCT/US2017/068352, filed on Dec. 22, 2017.
Claims priority of provisional application 62/438,909, filed on Dec. 23, 2016.
Prior Publication US 2023/0408490 A1, Dec. 21, 2023
Int. Cl. G01N 33/50 (2006.01); G01N 33/555 (2006.01)
CPC G01N 33/502 (2013.01) [G01N 33/555 (2013.01)] 10 Claims
 
1. A method of administering a red blood cell transfusion to a patient, wherein the red blood cell transfusion comprises red blood cells treated with a pathogen-inactivating compound β-alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester (S-303-treated RBCs), the method comprising:
a) testing a sample from the patient for presence of antibodies reactive to the S-303-treated RBCs according to a method comprising:
i) providing the sample from the patient, wherein the sample comprises serum or plasma;
ii) contacting the sample with a first substrate, wherein a moiety is bound to the surface of the first substrate, and wherein the surface-bound moiety resulted from treating the first substrate with a compound of Formula VIII:

OG Complex Work Unit Chemistry
where R1, R2, R3, R4, R5, R6, R7, and R8 are each —H; R20 is —H; and R21 is —R11—X-E, where —R11— is unsubstituted-C1-8alkyl-; X is independently —R11—; and E is N(R12)2; where —R12 is —CH2CH2-G, and where each G is independently —Cl, —Br, or —I, or a salt or stereoisomer thereof;
iii) assaying an amount of binding between antibodies from the sample and the surface-bound moiety of the first substrate as compared to a reference, wherein the binding between the antibodies and the surface-bound moiety indicates the presence of antibodies in the sample that are reactive to the S-303-treated RBCs, wherein the reference is a second substrate that lacks the surface-bound moiety, and the second substrate is the same as the first substrate;
b) determining whether the amount of binding is higher than the reference; and
c) administering the red blood cell transfusion to the patient in accordance with the determination that the amount of binding is not higher than the reference.